Accéder au contenu
Merck

Kurarinone from Sophora Flavescens Roots Triggers ATF4 Activation and Cytostatic Effects Through PERK Phosphorylation.

Molecules (Basel, Switzerland) (2019-08-30)
Sakiko Nishikawa, Yuka Itoh, Muneshige Tokugawa, Yasumichi Inoue, Ken-Ichi Nakashima, Yuka Hori, Chiharu Miyajima, Kou Yoshida, Daisuke Morishita, Nobumichi Ohoka, Makoto Inoue, Hajime Mizukami, Toshiaki Makino, Hidetoshi Hayashi
RÉSUMÉ

In response to cellular stresses, activating transcriptional factor 4 (ATF4) regulates the expression of both stress-relieving genes and apoptosis-inducing genes, eliciting cell fate determination. Since pharmacological activation of ATF4 exerts potent anti-tumor effects, modulators of ATF4 activation may have potential in cancer therapy. We herein attempted to identify small molecules that activate ATF4. A cell-based screening to monitor TRB3 promoter activation was performed using crude drugs used in traditional Japanese Kampo medicine. We found that an extract from Sophora flavescens roots exhibited potent TRB3 promoter activation. The activity-guided fractionation revealed that kurarinone was identified as the active ingredient. Intriguingly, ATF4 activation in response to kurarinone required PKR-like endoplasmic reticulum kinase (PERK). Moreover, kurarinone induced the cyclin-dependent kinase inhibitor p21 as well as cytostasis in cancer cells. Importantly, the cytostatic effect of kurarinone was reduced by pharmacological inhibition of PERK. These results indicate that kurarinone triggers ATF4 activation through PERK and exerts cytostatic effects on cancer cells. Taken together, our results suggest that modulation of the PERK-ATF4 pathway with kurarinone has potential as a cancer treatment.

MATÉRIAUX
Numéro du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Thapsigargine, ≥98% (HPLC), solid film
Sigma-Aldrich
Anti-phospho-PKR (Thr451) Antibody, Upstate®, from rabbit
Sigma-Aldrich
MISSION® esiRNA, targeting human EIF2AK3, AC104134.2